Upgrading and Downgrading of Prostate Cancer from B Incidence and Predictive Factors Using the Modified Gl in Tertiary Grades

Citation Report

#	ARTICLE	IF	CITATIONS
1	Current Challenges in Development of Differentially Expressed and Prognostic Prostate Cancer Biomarkers. Prostate Cancer, 2012, 2012, 1-9.	0.4	19
2	Gleason Score 6 Adenocarcinoma: Should It Be Labeled As Cancer?. Journal of Clinical Oncology, 2012, 30, 4294-4296.	0.8	162
3	Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. BMJ: British Medical Journal, 2012, 344, d7894-d7894.	2.4	211
4	Histology core‐specific evaluation of the <scp>E</scp>uropean <scp>S</scp>ociety of <scp>U</scp>rogenital <scp>R</scp>adiology (<scp>ESUR</scp>) standardised scoring system of multiparametric magnetic resonance imaging (<scp>mpMRI</scp>) of the prostate. BJU International, 2013, 112, 1080-1087.	1.3	71
5	Predictors of Gleason score upgrading in a large African-American population. International Urology and Nephrology, 2013, 45, 1257-1262.	0.6	17
6	MALDI-MS tissue imaging identification of biliverdin reductase B overexpression in prostate cancer. Journal of Proteomics, 2013, 91, 500-514.	1.2	45
7	Surgical Management of Prostate Cancer. Hematology/Oncology Clinics of North America, 2013, 27, 1111-1135.	0.9	11
8	Development and multi‐institutional validation of an upgrading risk tool for Gleason 6 prostate cancer. Cancer, 2013, 119, 3992-4002.	2.0	66
9	High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers. Molecular Oncology, 2013, 7, 1001-1011.	2.1	47
10	394 CONCORDANCE IN MOLECULAR MARKER STATUS BETWEEN BLADDER TUMORS AT TIME OF TRANSURETHRAL RESECTION AND SUBSEQUENT RADICAL CYSTECTOMY: RESULTS OF A 5-YEAR PROSPECTIVE STUDY. Journal of Urology, 2013, 189, .	0.2	0
12	Critical Evaluation of Magnetic Resonance Imaging Targeted, Transrectal Ultrasound Guided Transperineal Fusion Biopsy for Detection of Prostate Cancer. Journal of Urology, 2013, 190, 1380-1386.	0.2	178
13	Timing of Curative Treatment for Prostate Cancer: A Systematic Review. European Urology, 2013, 64, 204-215.	0.9	112
14	Contemporary Grading for Prostate Cancer: Implications for Patient Care. European Urology, 2013, 63, 892-901.	0.9	95
15	Defining the threshold for significant versus insignificant prostate cancer. Nature Reviews Urology, 2013, 10, 473-482.	1.9	98
16	Upgrading of <scp>G</scp>leason score and prostate volume: a clinicopathological analysis. BJU International, 2013, 111, 1310-1316.	1.3	24
17	Are Transrectal Prostate Biopsies Routinely Indicated in Patients with Incidentally Diagnosed Prostate Cancer following Transurethral Resection of the Prostate for Benign Disease?. Urologia Internationalis, 2013, 91, 397-403.	0.6	8
18	Overall- and Disease-Specific Survival in Prostata Cancer: Too Long to Wait?. Medical Radiology, 2013, , 65-73.	0.0	1
19	Can Contemporary Patients with Biopsy Gleason Score 3+4 Be Eligible for Active Surveillance?. PLoS ONE, 2014, 9, e109031.	1.1	6

#	Article	IF	Citations
20	Predicting the Gleason sum of a patient with a prostate biopsy core Gleason â‰¤7 and a prostate biopsy core Gleason â‰¥8. Canadian Urological Association Journal, 2014, 8, 476.	0.3	0
21	PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer. International Journal of Urology, 2014, 21, 1209-1214.	0.5	86
22	Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. British Journal of Cancer, 2014, 111, 1201-1212.	2.9	123
23	Upgrading and upstaging in prostate cancer: From prostate biopsy to radical prostatectomy. Molecular and Clinical Oncology, 2014, 2, 1145-1149.	0.4	39
24	Prognostic Histopathological and Molecular Markers on Prostate Cancer Needle-Biopsies: A Review. BioMed Research International, 2014, 2014, 1-12.	0.9	41
25	High nuclear karyopherin Î± 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy. Modern Pathology, 2014, 27, 96-106.	2.9	25
26	The impact of pathologic staging on the longâ€term oncologic outcomes of patients with clinically highâ€risk prostate cancer. Cancer, 2014, 120, 1656-1662.	2.0	24
27	Modeling grade progression in an active surveillance study. Statistics in Medicine, 2014, 33, 930-939.	0.8	41
28	Active Surveillance of Prostate Cancer in African American Men. Urology, 2014, 84, 1255-1262.	0.5	17
29	The likelihood of death from prostate cancer in men with favorable or unfavorable intermediateâ€risk disease. Cancer, 2014, 120, 1787-1793.	2.0	44
30	Higher rates of upgrading and upstaging in older patients undergoing radical prostatectomy and qualifying for active surveillance. BJU International, 2014, 114, 517-521.	1.3	33
31	Clinical significance of cancer in radical prostatectomy specimens: analysis from a contemporary series of 2900 men. Pathology, 2014, 46, 11-14.	0.3	8
32	Downgrading of biopsy based Gleason score in prostatectomy specimens. Journal of Clinical Pathology, 2014, 67, 313-318.	1.0	16
34	Physician Variation in Management of Low-Risk Prostate Cancer. JAMA Internal Medicine, 2014, 174, 1450.	2.6	104
35	The core of the matter: Using pathology instead of ultrasound to measure prostate volume. Canadian Urological Association Journal, 2014, 8, 232.	0.3	0
36	The status of surgery in the management of high-risk prostate cancer. Nature Reviews Urology, 2014, 11, 342-351.	1.9	34
37	When is Prostate Cancer Really Cancer?. Urologic Clinics of North America, 2014, 41, 339-346.	0.8	38
38	Agreement of Gleason Score on Prostate Biopsy and Radical Prostatectomy Specimen: Is There Improvement With Increased Number of Biopsy Cylinders and the 2005 Revised Gleason Scoring?. Clinical Genitourinary Cancer, 2014, 12, 160-166.	0.9	14

#	Article	IF	Citations
39	Abundant in vitro expression of the oncofetal ED-B-containing fibronectin translates into selective pharmacodelivery of 131I-L19SIP in a prostate cancer patient. Journal of Cancer Research and Clinical Oncology, 2014, 140, 35-43.	1.2	24
40	The Role of Magnetic Resonance Imaging in Delineating Clinically Significant Prostate Cancer. Urology, 2014, 83, 369-375.	0.5	60
41	Increased fatty acid synthase expression in prostate biopsy cores predicts higher Gleason score in radical prostatectomy specimen. BMC Clinical Pathology, 2014, 14, 3.	1.8	14
42	Î²III-Tubulin Overexpression Is an Independent Predictor of Prostate Cancer Progression Tightly Linked to ERG Fusion Status and PTEN Deletion. American Journal of Pathology, 2014, 184, 609-617.	1.9	48
43	â€œTo Measure Is To Know. If You Cannot Measure It, You Cannot Improve Itâ€ Statistical Modeling Cannot Compensate for Unmeasured Bias. European Urology, 2014, 65, 701-703.	0.9	5
44	NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer. Prostate, 2014, 74, 1012-1022.	1.2	10
45	Low free testosterone levels predict disease reclassification in men with prostate cancer undergoing active surveillance. BJU International, 2014, 114, 229-235.	1.3	48
46	Characteristics of modern Gleason 9/10 prostate adenocarcinoma: a single tertiary centre experience within the Republic of Ireland. World Journal of Urology, 2014, 32, 1067-1074.	1.2	10
47	Elevated fatty acid synthase expression in prostate needle biopsy cores predicts upgraded Gleason score in radical prostatectomy specimens. Prostate, 2014, 74, 90-96.	1.2	7
48	Current Clinical Presentation and Treatment of Localized Prostate Cancer in the United States. Journal of Urology, 2014, 192, 1650-1656.	0.2	37
49	The Prostate Cancer Susceptibility Variant rs2735839 Near <i>KLK3</i> Gene Is Associated with Aggressive Prostate Cancer and Can Stratify Gleason Score 7 Patients. Clinical Cancer Research, 2014, 20, 5133-5139.	3.2	31
50	Multiparametric 3T MRI for the prediction of pathological downgrading after radical prostatectomy in patients with biopsy-proven Gleason score 3â€‰+â€‰4 prostate cancer. European Radiology, 2014, 24, 3161-3170.	2.3	34
51	Local treatment of high risk prostate cancer: Role of surgery and radiation therapy. Cancer, 2014, 120, 1608-1610.	2.0	4
52	Patterns of failure after iodine-125 seed implantation for prostate cancer. Radiotherapy and Oncology, 2014, 112, 68-71.	0.3	4
53	Biopsy characteristics in men with a preoperative diagnosis of prostatic adenocarcinoma with high Gleason score (8-10) predict pathologic outcome in radical prostatectomy. Human Pathology, 2014, 45, 2006-2013.	1.1	5
54	Targeted Prostate Biopsies: The Complexity Behind a Simple Concept. European Urology, 2014, 66, 30-31.	0.9	5
55	The Effect of Differing Gleason Scores at Biopsy on the Odds of Upgrading and the Risk of Death From Prostate Cancer. Clinical Genitourinary Cancer, 2014, 12, e181-e187.	0.9	5
56	A Tertiary Gleason Pattern in the Prostatectomy Specimen and its Association with Adverse Outcome after Radical Prostatectomy. Journal of Urology, 2014, 192, 97-102.	0.2	34

#	Article	IF	Citations
57	Re: Prognostic Influence of the Third Gleason Grade in Prostatectomy Specimens. European Urology, 2014, 65, 498-499.	0.9	0
58	Magnetic Resonance Imaging-Ultrasound Fusion Biopsy for Prediction of Final Prostate Pathology. Journal of Urology, 2014, 192, 1367-1373.	0.2	121
59	Population Based Study of Predictors of Adverse Pathology among Candidates for Active Surveillance with Gleason 6 Prostate Cancer. Journal of Urology, 2014, 191, 350-357.	0.2	80
60	The prognostic significance of Gleason scores in metastatic prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 707-713.	0.8	48
61	The Role of Radical Prostatectomy and Lymph Node Dissection in Lymph Node–Positive Prostate Cancer: A Systematic Review of the Literature. European Urology, 2014, 66, 191-199.	0.9	100
62	The role of 3-tesla diffusion-weighted magnetic resonance imaging in selecting prostate cancer patients for active surveillance. Prostate International, 2014, 2, 169-175.	1.2	17
63	The prognostic significance of the 2014 International Society of Urological Pathology (ISUP) grading system for prostate cancer. Pathology, 2015, 47, 515-519.	0.3	48
65	Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate–risk disease. Cancer, 2015, 121, 2713-2719.	2.0	29
66	Importance of prostate volume in the stratification of patients with intermediate–risk prostate cancer. International Journal of Urology, 2015, 22, 555-561.	0.5	16
67	Disease–specific death and metastasis do not occur in patients with Gleason score ≤6 at radical prostatectomy. BJU International, 2015, 116, 230-235.	1.3	57
68	Aligning evidence and practice. Current Opinion in Urology, 2015, 25, 277-282.	0.9	1
69	Should Gleason 6 be labeled as cancer?. Current Opinion in Urology, 2015, 25, 238-245.	0.9	29
70	Prostate Biopsy and Radical Prostatectomy Gleason Score Correlation in Heterogenous Tumors. American Journal of Surgical Pathology, 2015, 39, 1213-1218.	2.1	28
71	Controlling RECK miR21 Promotes Tumor Cell Invasion and Is Related to Biochemical Recurrence in Prostate Cancer. Journal of Cancer, 2015, 6, 292-301.	1.2	46
72	Multiparametric magnetic resonance imaging for prostate cancer: A review and update for urologists. Korean Journal of Urology, 2015, 56, 487.	1.2	31
73	Elevated Serum MicroRNA Levels Associate with Absence of High-Grade Prostate Cancer in a Retrospective Cohort. PLoS ONE, 2015, 10, e0124245.	1.1	65
74	Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers. PLoS ONE, 2015, 10, e0128525.	1.1	26
75	High-Level HOOK3 Expression Is an Independent Predictor of Poor Prognosis Associated with Genomic Instability in Prostate Cancer. PLoS ONE, 2015, 10, e0134614.	1.1	16

#	ARTICLE	IF	CITATIONS
76	HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy. Oncotarget, 2015, 6, 12822-12834.	0.8	34
77	The correlation between the Gleason score of a transrectal prostate biopsy and a radical prostatectomy pathological report in patients with localized prostate cancer. Case Reports in Clinical Pathology, 2015, 3, .	0.0	0
78	Prostate biopsy concordance in a large population-based sample: a Surveillance, Epidemiology and End Results study. Journal of Clinical Pathology, 2015, 68, 453-457.	1.0	28
79	Multiparametric-MRI and Targeted Biopsies in the Management of Prostate Cancer Patients on Active Surveillance. Frontiers in Oncology, 2015, 5, 4.	1.3	8
80	A multicenter study shows <i>PTEN</i> deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. Prostate, 2015, 75, 1206-1215.	1.2	55
81	External validation and comparison of two nomograms predicting the probability of Gleason sum upgrading between biopsy and radical prostatectomy pathology in two patient populations: a retrospective cohort study. Japanese Journal of Clinical Oncology, 2015, 45, 1091-1095.	0.6	6
82	Active Surveillance. Surgical Pathology Clinics, 2015, 8, 581-585.	0.7	4
83	Development and Clinical Validation of an <i>In Situ</i> Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer. Clinical Cancer Research, 2015, 21, 2591-2600.	3.2	157
84	Clinical Implications of a Multiparametric Magnetic Resonance Imaging Based Nomogram Applied to Prostate Cancer Active Surveillance. Journal of Urology, 2015, 193, 1943-1949.	0.2	60
85	Diffusion-weighted magnetic resonance imaging for prediction of insignificant prostate cancer in potential candidates for active surveillance. European Radiology, 2015, 25, 1786-1792.	2.3	47
86	Comparison of systematic transrectal biopsy to transperineal magnetic resonance imaging/ultrasoundâ€fusion biopsy for the diagnosis of prostate cancer. BJU International, 2015, 116, 873-879.	1.3	71
87	Clinical role of pathological downgrading after radical prostatectomy in patients with biopsy confirmed Gleason score 3 + 4 prostate cancer. BJU International, 2015, 115, 81-86.	1.3	10
88	A urine-based methylation signature for risk stratification within low-risk prostate cancer. British Journal of Cancer, 2015, 112, 802-808.	2.9	16
89	Detection of Significant Prostate Cancer According to Anatomical Areas of Sampling Cores Obtained with Transrectal Systematic 12-Core Biopsy. Current Urology, 2015, 8, 91-95.	0.4	1
90	Mediumâ€term oncological outcomes for extended vs saturation biopsy and transrectal vs transperineal biopsy in active surveillance for prostate cancer. BJU International, 2015, 115, 884-891.	1.3	40
91	Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canaryâ€"Early Detection Research Network Active Surveillance Biopsy Risk Calculator. European Urology, 2015, 68, 1083-1088.	0.9	48
92	Validation of tertiary Gleason pattern 5 in Gleason score 7 prostate cancer as an independent predictor of biochemical recurrence and development of a prognostic model. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 71.e21-71.e26.	0.8	26
93	Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. Journal of Urology, 2015, 194, 343-349.	0.2	109

#	Article	IF	Citations
94	African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 70.e15-70.e22.	0.8	35
95	HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer. Experimental and Molecular Pathology, 2015, 98, 419-426.	0.9	26
96	Prevalence of High-grade or Insignificant Prostate Cancer in Korean Men With Prostate-specific Antigen Levels of 3.0-4.0Âng/mL. Urology, 2015, 85, 610-615.	0.5	6
97	Magnetic resonance imagingâ€"targeted vs. conventional transrectal ultrasoundâ€"guided prostate biopsy: Single-institution, matched cohort comparison. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 109.e1-109.e6.	0.8	10
98	Gleason stratifications prognostic for survival in men receiving definitive external beam radiation therapy for localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 71.e11-71.e19.	0.8	27
99	Comparison of clinical outcomes between upgraded pathologic Gleason score 3Â+Â4 and non-upgraded 3Â+Â4 prostate cancer among patients who are candidates for active surveillance. World Journal of Urology, 2015, 33, 1729-1734.	1.2	5
100	Guidance on Patient Consultation. Current Evidence for Prostate-Specific Antigen Screening in Healthy Men and Treatment Options for Men with Proven Localised Prostate Cancer. Current Urology Reports, 2015, 16, 28.	1.0	1
101	Conditional Probability of Reclassification in an Active Surveillance Program for Prostate Cancer. Journal of Urology, 2015, 193, 1950-1955.	0.2	32
102	Saccharomyces cerevisiaeâ€"like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusionâ€"positive and fusion-negative cancers. Human Pathology, 2015, 46, 514-523.	1.1	10
103	Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters. Carcinogenesis, 2015, 36, 1333-1340.	1.3	48
104	Comparison of Outcomes Between Preoperatively Potent Men Treated with Focal Versus Whole Gland Cryotherapy in a Matched Population. Journal of Endourology, 2015, 29, 1193-1198.	1.1	62
105	Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 437-442.	1.4	72
106	PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy. Modern Pathology, 2015, 28, 128-137.	2.9	136
107	Re: The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer. Journal of Urology, 2015, 194, 1825-1826.	0.2	4
108	The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion. BMC Cancer, 2015, 15, 538.	1.1	30
109	Automatic classification of prostate cancer Gleason scores from multiparametric magnetic resonance images. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6265-73.	3.3	322
110	Accuracy of MRI-Targeted in-Bore Prostate Biopsy According to the Gleason Score with Postprostatectomy Histopathologic Controlâ€"a Targeted Biopsy-Only Strategy with Limited Number of Cores. Academic Radiology, 2015, 22, 1409-1418.	1.3	16
111	Radical prostatectomy in high-risk and locally advanced prostate cancer: Mayo Clinic perspective. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 235-244.	0.8	27

#	Article	IF	Citations
112	Apparent diffusion coefficient ratio correlates significantly with prostate cancer gleason score at final pathology. Journal of Magnetic Resonance Imaging, 2015, 42, 446-453.	1.9	84
113	Clinically high-risk prostate cancer patients comprise a relevant number of cancers with overall favorable tumor characteristics. World Journal of Urology, 2015, 33, 85-92.	1.2	2
114	Relationship between Gleason score and apparent diffusion coefficients of diffusion-weighted magnetic resonance imaging in prostate cancer patients. Canadian Urological Association Journal, 2016, 10, 377.	0.3	20
115	Concordance in Biomarker Status Between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study. Bladder Cancer, 2016, 2, 91-99.	0.2	8
116	Nomograms for predicting Gleason upgrading in a contemporary Chinese cohort receiving radical prostatectomy after extended prostate biopsy: development and internal validation. Oncotarget, 2016, 7, 17275-17285.	0.8	10
117	Predicting Low-Risk Prostate Cancer from Transperineal Saturation Biopsies. Prostate Cancer, 2016, 2016, 1-7.	0.4	2
118	Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3Â+Â4Â=Â7 prostate cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 313-319.	1.4	39
119	An <i>Ex Vivo</i> Phantom Validation Study of an MRI-Transrectal Ultrasound Fusion Device for Targeted Prostate Biopsy. Journal of Endourology, 2016, 30, 685-691.	1.1	9
120	Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer. Prostate, 2016, 76, 259-272.	1.2	27
121	Prostate Cancer Prognosis Defined by the Combined Analysis of 8q, PTEN and ERG. Translational Oncology, 2016, 9, 575-582.	1.7	12
122	The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. American Journal of Surgical Pathology, 2016, 40, 244-252.	2.1	2,256
123	Improving the prediction of Gleason score upgrading: The role of prostate-specific antigen density. Revista Mexicana De Urologia, 2016, 76, 339-345.	0.0	0
124	PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance. Modern Pathology, 2016, 29, 764-771.	2.9	53
125	Preoperative Evaluation of Prostate Cancer Aggressiveness: Using ADC and ADC Ratio in Determining Gleason Score. American Journal of Roentgenology, 2016, 207, 114-120.	1.0	53
126	The Role of Pelvic Lymph Node Dissection During Radical Prostatectomy in Patients With Gleason 6 Intermediate-risk Prostate Cancer. Urology, 2016, 93, 141-146.	0.5	7
127	Detection of prostate cancer using temporal sequences of ultrasound data: a large clinical feasibility study. International Journal of Computer Assisted Radiology and Surgery, 2016, 11, 947-956.	1.7	34
128	Resultados oncológicos en enfermedad N1 posterior a la prostatectomía radical. Revista Mexicana De Urologia, 2016, 76, 23-28.	0.0	0
129	Prospective Evaluation of the Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection. Journal of Urology, 2016, 196, 690-696.	0.2	116

#	Article	IF	Citations
130	Perineural invasion on biopsy is associated with upstaging at radical prostatectomy in Gleason score 3 + 4 = 7 prostate cancer. Pathology International, 2016, 66, 629-632.	0.6	12
131	Current Gleason score 3Â+Â4Â=Â7: has it lost its significance compared with its historical counterpart?. BJU International, 2016, 117, 853-854.	1.3	0
132	Multiparametric magnetic resonance imaging: Current role in prostate cancer management. International Journal of Urology, 2016, 23, 550-557.	0.5	40
133	The role of radical prostatectomy as an initial approach in high-risk prostate cancer. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2016, 40, 353-360.	0.2	0
134	Preoperative Statin Use at the Time of Radical Prostatectomy Is Not Associated With Biochemical Recurrence or Pathologic Upgrading. Urology, 2016, 97, 153-159.	0.5	3
135	Does true Gleason pattern 3 merit its cancer descriptor?. Nature Reviews Urology, 2016, 13, 541-548.	1.9	18
136	Optimizing Active Surveillance. European Urology, 2016, 70, 909-911.	0.9	10
137	p16 upregulation is linked to poor prognosis in ERG negative prostate cancer. Tumor Biology, 2016, 37, 12655-12663.	0.8	20
138	Intraprostatic locations of tumor foci of higher grade missed by diagnostic prostate biopsy among potential candidates for active surveillance. Scientific Reports, 2016, 6, 36781.	1.6	6
139	Extreme Gleason Upgrading From Biopsy to Radical Prostatectomy: A Population-based Analysis. Urology, 2016, 96, 148-155.	0.5	12
140	Integration of multiparametric MRI into active surveillance of prostate cancer. Future Oncology, 2016, 12, 2513-2529.	1.1	6
141	Grading of prostatic adenocarcinoma: current state and prognostic implications. Diagnostic Pathology, 2016, 11, 25.	0.9	201
142	Analysis of topographical distribution of prostate cancer and related pathological findings in prostatectomy specimens using cMDX document architecture. Journal of Biomedical Informatics, 2016, 59, 240-247.	2.5	5
143	European Randomised Study of Screening for Prostate Cancer (<scp>ERSPC</scp>) risk calculators significantly outperform the Prostate Cancer Prevention Trial (<scp>PCPT</scp>) 2.0 in the prediction of prostate cancer: a multiâ€institutional study. BJU International, 2016, 118, 706-713.	1.3	60
144	What Are the Predictive Factors for Gleason Score Upgrade following RP?. Urologia Internationalis, 2016, 96, 1-4.	0.6	4
145	Prostate Cancer Grading: A Decade After the 2005 Modified Gleason Grading System. Archives of Pathology and Laboratory Medicine, 2016, 140, 1140-1152.	1.2	74
146	Gleason grading challenges in the diagnosis of prostate adenocarcinoma: experience of a single institution. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 213-218.	1.4	6
147	Size-adjusted Quantitative Gleason Score as a Predictor of Biochemical Recurrence after Radical Prostatectomy. European Urology, 2016, 70, 248-253.	0.9	17

#	ARTICLE	IF	CITATIONS
148	Papel de la prostatectomÃa radical como abordaje inicial en el tratamiento del cÃ¡ncer de prÃ³stata de alto riesgo. Actas UrolÃ³gicas EspaÃ±olas, 2016, 40, 353-360.	0.3	2
149	Gleason Misclassification Rate Is Independent of Number of Biopsy Cores in Systematic Biopsy. Urology, 2016, 91, 143-149.	0.5	23
152	PI-RADS version 2 for prediction of pathological downgrading after radical prostatectomy: a preliminary study in patients with biopsy-proven Gleason Score 7 (3+4) prostate cancer. European Radiology, 2016, 26, 3580-3587.	2.3	30
153	Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance. Journal of Urology, 2016, 195, 1409-1414.	0.2	98
154	Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the GÃ¶teborg Randomised Screening Trial. European Urology, 2016, 70, 566-573.	0.9	65
155	The Significance of Accurate Determination of Gleason Score for Therapeutic Options and Prognosis of Prostate Cancer. Pathology and Oncology Research, 2016, 22, 349-356.	0.9	19
156	Should the involvement of skeletal muscle by prostatic adenocarcinoma be reported on biopsies?. Human Pathology, 2016, 49, 10-14.	1.1	1
157	The Diagnostic Performance of Multiparametric Magnetic Resonance Imaging to Detect Significant Prostate Cancer. Journal of Urology, 2016, 195, 1428-1435.	0.2	124
158	The value of ADC, T2 signal intensity, and a combination of both parameters to assess Gleason score and primary Gleason grades in patients with known prostate cancer. Acta Radiologica, 2016, 57, 107-114.	0.5	36
159	A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. European Urology, 2016, 69, 428-435.	0.9	1,039
160	Salvage radical prostatectomy for recurrent prostate cancer: verification of European Association of Urology guideline criteria. BJU International, 2016, 117, 55-61.	1.3	43
161	Diffusionâ€weighted imaging predicts upgrading of Gleason score in biopsyâ€proven low grade prostate cancers. BJU International, 2017, 119, 57-66.	1.3	20
162	Quantified Clinical Risk Change as an End Point During Prostate Cancer Active Surveillance. European Urology, 2017, 72, 329-332.	0.9	8
163	Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer. Clinical Cancer Research, 2017, 23, 311-319.	3.2	65
164	Clinical Applications of Molecular Imaging in the Management of Prostate Cancer. PET Clinics, 2017, 12, 185-192.	1.5	12
165	Global Gleason grade groups in prostate cancer: concordance of biopsy and radical prostatectomy grades and predictors of upgrade and downgrade. Histopathology, 2017, 70, 1098-1106.	1.6	42
166	Utility of computed diffusionâ€weighted MRI for predicting aggressiveness of prostate cancer. Journal of Magnetic Resonance Imaging, 2017, 46, 490-496.	1.9	20
167	Multiparametric Magnetic Resonance/Ultrasound Fusion Prostate Biopsy: Number and Spatial Distribution of Cores for Better Index Tumor Detection and Characterization. Journal of Urology, 2017, 198, 58-64.	0.2	52

#	ARTICLE	IF	CITATIONS
168	Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4. Clinical Cancer Research, 2017, 23, 3823-3833.	3.2	43
169	Prostate Imaging Reporting and Data System, Version 2, Assessment Categories and Pathologic Outcomes in Patients With Gleason Score 3 + 4 = 7 Prostate Cancer Diagnosed at Biopsy. American Journal of Roentgenology, 2017, 208, 1037-1044.	1.0	11
170	Prostate-specific antigen density is predictive of outcome in suboptimal prostate seed brachytherapy. Brachytherapy, 2017, 16, 348-352.	0.2	4
171	Role of Magnetic Resonance Imaging in Prostate Cancer Assessment. Current Clinical Urology, 2017, , 161-176.	0.0	0
172	Transfer learning from RF to B-mode temporal enhanced ultrasound features for prostate cancer detection. International Journal of Computer Assisted Radiology and Surgery, 2017, 12, 1111-1121.	1.7	25
173	Postoperative upgrading of prostate cancer in men ≥75 years: a propensity score-matched analysis. World Journal of Urology, 2017, 35, 1517-1524.	1.2	17
174	Detection and grading of prostate cancer using temporal enhanced ultrasound: combining deep neural networks and tissue mimicking simulations. International Journal of Computer Assisted Radiology and Surgery, 2017, 12, 1293-1305.	1.7	36
175	Re: Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone: Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above. Journal of Urology, 2017, 198, 445-446.	0.2	0
176	Blinded review of archival radical prostatectomy specimens supports that contemporary Gleason score 6 prostate cancer lacks metastatic potential. Prostate, 2017, 77, 1076-1081.	1.2	6
177	Grade Group Underestimation in Prostate Biopsy: Predictive Factors and Outcomes in Candidates for Active Surveillance. Clinical Genitourinary Cancer, 2017, 15, e907-e913.	0.9	11
178	Two-Stage Biomarker Protocols for Improving the Precision of Early Detection of Prostate Cancer. Medical Decision Making, 2017, 37, 815-826.	1.2	12
179	Gleason sum upgrading between biopsy and radical prostatectomy in Chinese population: Updated nomograms. Actas Urológicas Españolas (English Edition), 2017, 41, 162-171.	0.2	2
180	Prospective Evaluation of PI-RADS™ Version 2 Using the International Society of Urological Pathology Prostate Cancer Grade Group System. Journal of Urology, 2017, 198, 583-590.	0.2	127
181	Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers. Neoplasia, 2017, 19, 279-287.	2.3	16
183	Commentary on: Padeliporfin Vascular-targeted Photodynamic Therapy Versus Active Surveillance in Men With Low-risk Prostate Cancer (CLIN1001 PCM301): An Open-label, Phase 3, Randomized Controlled Trial. Urology, 2017, 104, 7-8.	0.5	1
184	Transperineal biopsies of MRI-detected aggressive index lesions in low- and intermediate-risk prostate cancer patients: Implications for treatment decision. Brachytherapy, 2017, 16, 201-206.	0.2	3
185	Extraprostatic Extension Is Extremely Rare for Contemporary Gleason Score 6 Prostate Cancer. European Urology, 2017, 72, 455-460.	0.9	28
186	High-Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer. Prostate, 2017, 77, 1528-1538.	1.2	16

#	ARTICLE	IF	CITATIONS
187	A Prospective Comparison of Selective Multiparametric Magnetic Resonance Imaging Fusion-Targeted and Systematic Transrectal Ultrasound-Guided Biopsies for Detecting Prostate Cancer in Men Undergoing Repeated Biopsies. Urologia Internationalis, 2017, 99, 384-391.	0.6	24
188	Diffusion Kurtosis Imaging Helps to Predict Upgrading in Biopsy-Proven Prostate Cancer With a Gleason Score of 6. American Journal of Roentgenology, 2017, 209, 1081-1087.	1.0	10
189	Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer. Neoplasia, 2017, 19, 707-715.	2.3	65
190	Seminal plasma enables selection and monitoring of active surveillance candidates using nuclear magnetic resonance-based metabolomics: A preliminary investigation. Prostate International, 2017, 5, 149-157.	1.2	14
191	Epigenetic risk score improves prostate cancer risk assessment. Prostate, 2017, 77, 1259-1264.	1.2	21
192	Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate cancer. Scientific Reports, 2017, 7, 2056.	1.6	27
193	Use of a 17-Gene Prognostic Assay in Contemporary Urologic Practice: Results of an Interim Analysis in an Observational Cohort. Urology, 2017, 107, 67-75.	0.5	36
194	Prognostic value of Prostate Imaging and Data Reporting System (PI-RADS) v. 2 assessment categories 4 and 5 compared to histopathological outcomes after radical prostatectomy. Journal of Magnetic Resonance Imaging, 2017, 46, 257-266.	1.9	32
195	The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality. Journal of Urology, 2017, 197, 1060-1067.	0.2	10
196	Prostate imaging reporting and data system version 2 (PI-RADS v2): a pictorial review. Abdominal Radiology, 2017, 42, 278-289.	1.0	56
197	Validity of the Cancer of the Prostate Risk Assessment Score Derived From Targeted Biopsy: Modeling Evidence From Ultrasound Lesion-Directed Biopsy. Clinical Genitourinary Cancer, 2017, 15, 93-99.	0.9	1
198	A Bayesian Hierarchical Model for Prediction of Latent Health States from Multiple Data Sources with Application to Active Surveillance of Prostate Cancer. Biometrics, 2017, 73, 625-634.	0.8	23
199	Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore versus Magnetic Resonance Imaging-transrectal Ultrasound fusion versus Cognitive Registration. Is There a Preferred Technique?. European Urology, 2017, 71, 517-531.	0.9	326
200	Infragradación de la biopsia de próstata respecto a la pieza de prostatectomÃa la población china: nomogramas actualizados. Actas Urológicas Españolas, 2017, 41, 162-171.	0.3	3
201	The Emerging Role of MRI in Prostate Cancer Active Surveillance and Ongoing Challenges. American Journal of Roentgenology, 2017, 208, 131-139.	1.0	66
202	A biopsy-integrated algorithm for determining Gleason 6 upgrading risk stratifies risk of active surveillance failure in prostate cancer. World Journal of Urology, 2017, 35, 729-735.	1.2	8
203	Management of prostate cancer patients with locally adverse pathologic features after radical prostatectomy: feasibility of active surveillance for cases with Gleason grade 3Â+Â4Â=Â7. Journal of Cancer Research and Clinical Oncology, 2017, 143, 123-129.	1.2	5
204	Active Surveillance Following Modified Transperineal Template Guided Saturation Biopsy Demonstrates a Low Rate of Progression and Conversion to Radical Treatment, with Age and PSA Associated with Upgrading, Upstaging and Treatment. Advances in Cancer Prevention, 2017, 02, .	0.2	0

#	Article	IF	Citations
205	Association of PTEN expression with biochemical recurrence in prostate cancer: results based on previous reports. OncoTargets and Therapy, 2017, Volume 10, 5089-5097.	1.0	6
206	High-Level Î³-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer. International Journal of Molecular Sciences, 2017, 18, 286.	1.8	30
207	Prognostic Value of the New Prostate Cancer International Society of Urological Pathology Grade Groups. Frontiers in Medicine, 2017, 4, 157.	1.2	21
208	The Importance of Histology and Pathology in Mass Spectrometry Imaging. Advances in Cancer Research, 2017, 134, 1-26.	1.9	19
209	Oncological outcomes in an Australian cohort according to the new prostate cancer grading groupings. BMC Cancer, 2017, 17, 537.	1.1	3
210	Application of ultrasound imaging biomarkers (HistoScanningâ„¢) improves staging reliability of prostate biopsies. BMC Research Notes, 2017, 10, 579.	0.6	1
211	Prostate-specific antigen 10â€"20 ng/mL: A predictor of degree of upgrading to â‰¥8 among patients with biopsy Gleason score 6. Investigative and Clinical Urology, 2017, 58, 90.	1.0	16
212	The impact of the 2005 International Society of Urological Pathology Gleason grading consensus on active surveillance for prostate cancer. Central European Journal of Urology, 2017, 70, 344-348.	0.2	2
213	The Modulating Effects of Benign Prostate Enlargement Medications on Upgrading Predictors in Patients with Gleason 6 at Biopsy. Current Urology, 2017, 10, 97-104.	0.4	2
214	Validation of a 10-gene molecular signature for predicting biochemical recurrence and clinical metastasis in localized prostate cancer. Journal of Cancer Research and Clinical Oncology, 2018, 144, 883-891.	1.2	24
215	Pathology of Prostate Cancer. Molecular Pathology Library, 2018, , 37-56.	0.1	1
216	Prostate Cancer Molecular Prognosis. Molecular Pathology Library, 2018, , 503-522.	0.1	2
217	Contrast enhanced ultrasound (CEUS) with MRI image fusion for monitoring focal therapy of prostate cancer with high intensity focused ultrasound (HIFU)1. Clinical Hemorheology and Microcirculation, 2018, 69, 93-100.	0.9	24
218	3 + 4 = 6? Implications of the stratification of localized Gleason 7 prostate cancer by number and percentage of positive biopsy cores in selecting patients for active surveillance. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2018, 42, 103-113.	0.2	2
219	Pilot study for supervised target detection applied to spatially registered multiparametric MRI in order to non-invasively score prostate cancer. Computers in Biology and Medicine, 2018, 94, 65-73.	3.9	12
220	Costâ€effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer. BJU International, 2018, 122, 50-58.	1.3	49
221	Targeted biopsy. Current Opinion in Urology, 2018, 28, 219-226.	0.9	6
222	Concordance of Gleason grading with three-dimensional ultrasound systematic biopsy and biopsy core pre-embedding. World Journal of Urology, 2018, 36, 863-869.	1.2	3

#	Article	IF	Citations
223	Pathologic Outcomes of Candidates for Active Surveillance Undergoing Radical Prostatectomy: Results from a Contemporary Turkish Patient Cohort. Urologia Internationalis, 2018, 100, 43-49.	0.6	5
224	The Gleason pattern 4 in radical prostatectomy specimens in current practice - Quantification, morphology and concordance with biopsy. Annals of Diagnostic Pathology, 2018, 34, 13-17.	0.6	5
225	The new Epstein gleason score classification significantly reduces upgrading in prostate cancer patients. European Journal of Surgical Oncology, 2018, 44, 835-839.	0.5	27
226	Incidence of Extraprostatic Extension at Radical Prostatectomy with Pure Gleason Score 3 + 3 = 6 (Grade Group 1) Cancer: Implications for Whether Gleason Score 6 Prostate Cancer Should be Renamed "Not Cancer" and for Selection Criteria for Active Surveillance. Journal of Urology, 2018, 199, 1482-1487.	0.2	27
227	MR Imaging for Prostate Cancer Screening and Active Surveillance. Radiologic Clinics of North America, 2018, 56, 251-261.	0.9	6
228	Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 158.e1-158.e6.	0.8	10
229	Prostate cancer grading: a decade after the 2005 modified system. Modern Pathology, 2018, 31, 47-63.	2.9	83
230	Toward a real-time system for temporal enhanced ultrasound-guided prostate biopsy. International Journal of Computer Assisted Radiology and Surgery, 2018, 13, 1201-1209.	1.7	8
231	A 17-Gene Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate Biopsy. Journal of Urology, 2018, 200, 564-572.	0.2	28
232	Role of PI-RADS Version 2 for Prediction of Upgrading in Biopsy-Proven Prostate Cancer With Gleason Score 6. Clinical Genitourinary Cancer, 2018, 16, 281-287.	0.9	27
233	Molecular correlates of intermediate- and high-risk localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 368-374.	0.8	5
234	Mesoscopic characterization of prostate cancer using Raman spectroscopy: potential for diagnostics and therapeutics. BJU International, 2018, 122, 326-336.	1.3	49
235	Integrating Tertiary Gleason 5 Patterns into Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. European Urology, 2018, 73, 674-683.	0.9	40
236	New prostate cancer prognostic grade group (PGG): Can multiparametric MRI (mpMRI) accurately separate patients with low-, intermediate-, and high-grade cancer?. Abdominal Radiology, 2018, 43, 702-712.	1.0	15
237	Adverse Pathologic Findings for Men Electing Immediate Radical Prostatectomy. JAMA Oncology, 2018, 4, 89.	3.4	52
238	Prostate-specific Antigen Density Is a Good Predictor of Upstaging and Upgrading, According to the New Grading System: The Keys We Are Seeking May Be Already in Our Pocket. Urology, 2018, 111, 129-135.	0.5	27
239	Â¿3 + 4Â= 6? Implicaciones de la estratificaciÃ³n del cÃ¡ncer de prÃ³stata localizado Gleason 7 por nÃºmero y porcentaje de cilindros positivos de biopsia en la selecciÃ³n de pacientes para vigilancia activa. Actas UrolÃ³gicas EspaÃ±olas, 2018, 42, 103-113.	0.3	2
240	Defining Novel and Practical Metrics to Assess the Deliverables of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy. Journal of Urology, 2018, 199, 969-975.	0.2	5

#	Article	IF	Citations
241	Most Gleason 8 Biopsies are Downgraded at Prostatectomyâ€"Does 4 + 4 = 7?. Journal of Urology, 2018, 199, 706-712.	0.2	19
242	Optimizing active surveillance strategies to balance the competing goals of early detection of grade progression and minimizing harm from biopsies. Cancer, 2018, 124, 698-705.	2.0	12
243	Genomic Gain of 16p13.3 in Prostate Cancer Predicts Poor Clinical Outcome after Surgical Intervention. Molecular Cancer Research, 2018, 16, 115-123.	1.5	12
244	Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer. Translational Andrology and Urology, 2018, 7, S484-S489.	0.6	14
245	Aggressive Cancer Behavior of Latent Gleason Pattern 5 in Prostatectomy Specimens. Anticancer Research, 2018, 38, 6529-6535.	0.5	2
246	Concordance of â€œCase Levelâ€•Global, Highest, and Largest Volume Cancer Grade Group on Needle Biopsy Versus Grade Group on Radical Prostatectomy. American Journal of Surgical Pathology, 2018, 42, 1522-1529.	2.1	23
247	Advances in Medical Imaging Technology for Accurate Detection of Prostate Cancer. , 0, , .		0
248	Current topics on prostate and bladder pathology. Surgical and Experimental Pathology, 2018, 1, .	0.2	1
249	Urologic Pathology. Surgical Pathology Clinics, 2018, 11, 893-901.	0.7	2
250	High levels of glioma tumor suppressor candidate region gene 1 predicts a poor prognosis for prostate cancer. Oncology Letters, 2018, 16, 6749-6755.	0.8	11
251	Risk of upgrading from prostate biopsy to radical prostatectomy pathology: Is magnetic resonance imaging-guided biopsy more accurate?. Journal of Cancer, 2018, 9, 3634-3639.	1.2	22
252	Serum thymidine kinase 1 is associated with Gleason score of patients with prostate carcinoma. Oncology Letters, 2018, 16, 6171-6180.	0.8	2
253	Effects of pathological upstaging or upgrading on metastasis and cancerâ€specific mortality in men with clinical lowâ€risk prostate cancer. BJU International, 2018, 122, 1003-1009.	1.3	35
254	Not All Multiparametric Magnetic Resonance Imagingâ€"targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection of Clinically Significant Prostate Cancer. European Urology Oncology, 2018, 1, 120-128.	2.6	55
255	Tissue proteomics studies in the investigation of prostate cancer. Expert Review of Proteomics, 2018, 15, 593-611.	1.3	8
256	Deep Recurrent Neural Networks for Prostate Cancer Detection: Analysis of Temporal Enhanced Ultrasound. IEEE Transactions on Medical Imaging, 2018, 37, 2695-2703.	5.4	57
258	13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer. Genes Chromosomes and Cancer, 2018, 57, 504-512.	1.5	35
259	Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. European Urology, 2018, 74, 722-728.	0.9	70

#	ARTICLE	IF	CITATIONS
260	ADC Metrics From Multiparametric MRI: Histologic Downgrading of Gleason Score 9 or 10 Prostate Cancers Diagnosed at Nontargeted Transrectal Ultrasoundâ€"Guided Biopsy. American Journal of Roentgenology, 2018, 211, W158-W165.	1.0	7
261	Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1376-1383.	1.1	9
262	Clinical and pathologic factors predicting reclassification in active surveillance cohorts. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2018, 44, 440-451.	0.7	13
263	Metabolic syndrome increases the risk of upgrading and upstaging in patients with prostate cancer on biopsy: a radical prostatectomy multicenter cohort study. Prostate Cancer and Prostatic Diseases, 2018, 21, 438-445.	2.0	14
264	Advances in Urologic Imaging. Urologic Clinics of North America, 2018, 45, 503-524.	0.8	27
266	Gleason score assignment is the sole responsibility of the pathologist. Histopathology, 2018, 73, 5-7.	1.6	12
267	Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions. European Urology, 2019, 75, 385-396.	0.9	200
268	The combination of PTEN deletion and 16p13.3 gain in prostate cancer provides additional prognostic information in patients treated with radical prostatectomy. Modern Pathology, 2019, 32, 128-138.	2.9	5
269	Urinary DNA methylation biomarkers for prediction of prostate cancer upgrading and upstaging. Clinical Epigenetics, 2019, 11, 115.	1.8	24
270	Pathological Assessment of Prostate Cancer. , 2019, , 159-177.		0
271	Extent and predictors of grade upgrading and downgrading in an Australian cohort according to the new prostate cancer grade groupings. Asian Journal of Urology, 2019, 6, 321-329.	0.5	7
272	Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy. Neoplasia, 2019, 21, 872-881.	2.3	5
273	The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer. Tumor Biology, 2019, 41, 101042831882481.	0.8	9
274	^{18}F-Choline PET/mpMRI for Detection of Clinically Significant Prostate Cancer: Part 2. Cost-Effectiveness Analysis. Journal of Nuclear Medicine, 2019, 60, 1705-1712.	2.8	12
275	Pathological upgrading in prostate cancer treated with surgery in the United Kingdom: trends and risk factors from the British Association of Urological Surgeons Radical Prostatectomy Registry. BMC Urology, 2019, 19, 94.	0.6	25
276	High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer. BMC Cancer, 2019, 19, 944.	1.1	4
277	Proportion of cores with the highest Gleason grade group among positive cores on prostate biopsy: does this affect the probability of upgrading or downgrading?. Scandinavian Journal of Urology, 2019, 53, 372-377.	0.6	5
278	Comparison of Magnetic Resonance Imaging-stratified Clinical Pathways and Systematic Transrectal Ultrasound-guided Biopsy Pathway for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials. European Urology Oncology, 2019, 2, 605-616.	2.6	30

#	Article	IF	Citations
279	Total testosterone density predicts high tumor load and disease reclassification of prostate cancer: results in 144 low-risk patients who underwent radical prostatectomy. International Urology and Nephrology, 2019, 51, 2169-2180.	0.6	9
280	Perioperative and oncological outcomes of radical prostatectomy for high‐risk prostate cancer in the UK: an analysis of surgeon‐reported data. BJU International, 2019, 124, 441-448.	1.3	11
281	Evaluation of the accuracy of multiparametric <scp>MRI</scp> for predicting prostate cancer pathology and tumour staging in the real world: an multicentre study. BJU International, 2019, 124, 297-301.	1.3	23
282	Optimizing prostate cancer accumulating model: combined PI-RADS v2 with prostate specific antigen and its derivative data. Cancer Imaging, 2019, 19, 26.	1.2	6
283	Prostate cancer aggressive prediction: preponderant diagnostic performances of intravoxel incoherent motion (IVIM) imaging and diffusion kurtosis imaging (DKI) beyond ADC at 3.0 T scanner with gleason score at final pathology. Abdominal Radiology, 2019, 44, 3441-3452.	1.0	20
284	PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway. Radiology, 2019, 292, 464-474.	3.6	162
285	Impact of bilateral biopsy-detected prostate cancer on an active surveillance population. BMC Urology, 2019, 19, 26.	0.6	2
286	Influence of African American race on the association between preoperative biopsy grade group and adverse histopathologic features of radical prostatectomy. Cancer, 2019, 125, 3025-3032.	2.0	3
287	Concordance of cribriform architecture in matched prostate cancer biopsy and radical prostatectomy specimens. Histopathology, 2019, 75, 338-345.	1.6	22
288	Circulating blood miRNAs for prostate cancer risk stratification: miRroring the underlying tumor biology with liquid biopsies . Research and Reports in Urology, 2019, Volume 11, 29-42.	0.6	8
289	The effect of time from biopsy to radical prostatectomy on adverse pathologic outcomes . Research and Reports in Urology, 2019, Volume 11, 53-60.	0.6	11
290	Joint Prostate Cancer Detection and Gleason Score Prediction in mp-MRI via FocalNet. IEEE Transactions on Medical Imaging, 2019, 38, 2496-2506.	5.4	133
291	The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer. Urology, 2019, 130, 1-12.	0.5	56
292	Assessment of prostate cancer prognostic Gleason grade group using zonal‐specific features extracted from biparametric <scp>MRI</scp> using a <scp>KNN</scp> classifier. Journal of Applied Clinical Medical Physics, 2019, 20, 146-153.	0.8	26
293	Evolution, controversies and the future of prostate cancer grading. Pathology International, 2019, 69, 55-66.	0.6	6
294	Downgrading of Grade Group After Radical Prostatectomy: Comparison of Multiparametric Magnetic Resonance Imaging Guided Fusion Biopsy and Standard 12-Core Biopsy. Urology, 2019, 127, 80-85.	0.5	12
295	Estudio de concordancia entre los resultados de la puntuaciÃ³n de Gleason de biopsias de prÃ³stata y los de la prostatectomÃa radical en pacientes con cÃ¡ncer de prÃ³stata localizado. Revista Facultad De Medicina, 2019, 67, 209-214.	0.0	0
296	Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. The Cochrane Library, 2019, 2019, CD012663.	1.5	234

#	ARTICLE	IF	CITATIONS
298	Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unnecessary prostate biopsies. BJU International, 2019, 123, 826-833.	1.3	25
299	Integrating tertiary Gleason pattern 5 into the ISUP grading system improves prediction of biochemical recurrence in radical prostatectomy patients. Modern Pathology, 2019, 32, 122-127.	2.9	16
300	Prostate cancer classification with multiparametric MRI transfer learning model. Medical Physics, 2019, 46, 756-765.	1.6	98
301	Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance. Prostate Cancer and Prostatic Diseases, 2019, 22, 399-405.	2.0	53
302	Intraductal carcinoma of the prostate (IDC–P) lowers apparent diffusion coefficient (ADC) values among intermediate risk prostate cancers. Journal of Magnetic Resonance Imaging, 2019, 50, 279-287.	1.9	12
303	Loss of CCAAT–enhancer–binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers. Prostate, 2019, 79, 302-311.	1.2	4
304	Urotensin II receptor expression in prostate cancer patients: A new possible marker. Prostate, 2019, 79, 288-294.	1.2	7
305	A 17-gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and Utility. Urology, 2019, 126, 76-82.	0.5	36
306	Automatic Needle Segmentation and Localization in MRI With 3-D Convolutional Neural Networks: Application to MRI-Targeted Prostate Biopsy. IEEE Transactions on Medical Imaging, 2019, 38, 1026-1036.	5.4	42
307	Constructing and Pilot Testing a Novel Prostate Magnetic Resonance Imaging/Ultrasound Fusion Biopsy Phantom. Urology, 2019, 124, 33-37.	0.5	6
308	Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy. Abdominal Radiology, 2019, 44, 1520-1527.	1.0	28
309	Parallels Between Low-Risk Prostate Cancer and Thyroid Cancer. JAMA Oncology, 2019, 5, 556.	3.4	24
310	Pathological Assessment of Prostate Cancer. , 2019, , 1-19.		0
311	Accuracy of multiparametric magnetic resonance imaging to detect significant prostate cancer and index lesion location. ANZ Journal of Surgery, 2019, 89, 106-110.	0.3	6
312	Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance. BJU International, 2019, 123, 846-853.	1.3	21
313	Role of Metabolic Syndrome on Perioperative and Oncological Outcomes at Radical Prostatectomy in a Low-risk Prostate Cancer Cohort Potentially Eligible for Active Surveillance. European Urology Focus, 2019, 5, 425-432.	1.6	11
314	Analysis of Diffusion-weighted MR Images Based on a Gamma Distribution Model to Differentiate Prostate Cancers with Different Gleason Score. Magnetic Resonance in Medical Sciences, 2020, 19, 40-47.	1.1	4
315	Methylation Markers in Prostate Biopsies Are Prognosticators for Late Biochemical Recurrence and Therapy after Surgery in Prostate Cancer Patients. Journal of Molecular Diagnostics, 2020, 22, 30-39.	1.2	3

#	ARTICLE	IF	CITATIONS
316	Circulating mRNA signature as a marker for high-risk prostate cancer. Carcinogenesis, 2020, 41, 139-145.	1.3	12
317	Persistent Discordance in Grade, Stage, and NCCN Risk Stratification in Men Undergoing Targeted Biopsy and Radical Prostatectomy. Urology, 2020, 135, 117-123.	0.5	17
318	Impact of biparametric prebiopsy prostate magnetic resonance imaging on the diagnostics of clinically significant prostate cancer in biopsy naÃ¯ve men. Scandinavian Journal of Urology, 2020, 54, 7-13.	0.6	0
319	Overall, specific, and metastasisâ€free survival of Afroâ€Caribbean men with pathological Gleason 6 prostate cancer. Prostate, 2020, 80, 329-335.	1.2	0
320	The clinical predictive factors and postoperative histopathological parameters associated with upgrading after radical prostatectomy: A contemporary analysis with grade groups. Prostate, 2020, 80, 225-234.	1.2	9
321	Prognostic Value of Pretreatment MRI in Patients With Prostate Cancer Treated With Radiation Therapy: A Systematic Review and Meta-Analysis. American Journal of Roentgenology, 2020, 214, 597-604.	1.0	21
322	Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer. World Journal of Urology, 2020, 38, 2185-2196.	1.2	10
323	Should all prostate needle biopsy Gleason score 4â€+â€4â€=â€8 prostate cancers be high risk? Implications for shared decision-making and patient counselling. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 78.e1-78.e6.	0.8	6
324	Safety and efficacy of guided biopsy. , 2020, , 431-444.		0
325	Association between PSA density and pathologically significant prostate cancer: The impact of prostate volume. Prostate, 2020, 80, 1444-1449.	1.2	40
326	Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence. BioMed Research International, 2020, 2020, 1-13.	0.9	7
327	Effect of core needle biopsy number on intraductal carcinoma of the prostate (IDC-P) diagnosis in patients with metastatic hormone-sensitive prostate cancer. International Journal of Clinical Oncology, 2020, 25, 2130-2137.	1.0	2
328	High B7â€H3 expression is linked to increased risk of prostate cancer progression. Pathology International, 2020, 70, 733-742.	0.6	16
329	AZGP1 Protein Expression in Hormone-NaÃ¯ve Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy. Diagnostics, 2020, 10, 520.	1.3	1
330	Predictors of ISUP score upgrade in patients with low-risk prostate cancer. Tumori, 2021, 107, 030089162094395.	0.6	2
331	Noninvasive biomarkers to guide intervention: toward personalized patient management in prostate cancer. Expert Review of Precision Medicine and Drug Development, 2020, 5, 383-400.	0.4	4
332	Reply to The risk factors of upgrading in prostate cancer. Cancer, 2020, 126, 4432-4433.	2.0	1
333	Prediction of Radioresistant Prostate Cancer Based on Differentially Expressed Proteins. Urologia Internationalis, 2021, 105, 316-327.	0.6	3

#	Article	IF	Citations
334	Predicting Prostate Cancer Upgrading of Biopsy Gleason Grade Group at Radical Prostatectomy Using Machine Learning-Assisted Decision-Support Models. Cancer Management and Research, 2020, Volume 12, 13099-13110.	0.9	10
335	Prediction of prostate cancer Gleason score upgrading from biopsy to radical prostatectomy using pre-biopsy multiparametric MRI PIRADS scoring system. Scientific Reports, 2020, 10, 7722.	1.6	39
336	Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 625-636.	1.4	6
337	Bioptic intraprostatic chronic inflammation predicts adverse pathology at radical prostatectomy in patients with low-grade prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 793.e19-793.e25.	0.8	13
338	A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy. British Journal of Cancer, 2020, 123, 604-609.	2.9	9
339	Radiomics Based on MRI as a Biomarker to Guide Therapy by Predicting Upgrading of Prostate Cancer From Biopsy to Radical Prostatectomy. Journal of Magnetic Resonance Imaging, 2020, 52, 1239-1248.	1.9	26
340	Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion. Molecular Medicine, 2020, 26, 24.	1.9	5
341	Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusion–positive prostate cancers. International Journal of Cancer, 2020, 147, 575-583.	2.3	4
342	A pilot window-of-opportunity study of preoperative fluvastatin in localized prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 630-637.	2.0	31
343	MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. New England Journal of Medicine, 2020, 382, 917-928.	13.9	515
344	Downgrading of grade group 2 intermediate–risk prostate cancer from biopsy to radical prostatectomy: Comparison of outcomes and predictors to identify potential candidates for active surveillance. Cancer, 2020, 126, 1632-1639.	2.0	8
345	The Impact of Prostate Cancer Upgrading and Upstaging on Biochemical Recurrence and Cancer-Specific Survival. Medicina (Lithuania), 2020, 56, 61.	0.8	12
346	MiRNA-Based Inspired Approach in Diagnosis of Prostate Cancer. Medicina (Lithuania), 2020, 56, 94.	0.8	10
347	Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year results. World Journal of Urology, 2020, 38, 3101-3111.	1.2	2
348	Clinical outcome comparison of Grade Group 1 and Grade Group 2 prostate cancer with and without cribriform architecture at the time of radical prostatectomy. Histopathology, 2020, 76, 755-762.	1.6	18
349	High CHK2 protein expression is a strong and independent prognostic feature in ERG negative prostate cancer. Pathology, 2020, 52, 421-430.	0.3	5
350	Systematic review and meta-analysis comparing cognitive vs. image-guided fusion prostate biopsy for the detection of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 734.e19-734.e25.	0.8	32
351	Upregulation of PTTG1 is associated with poor prognosis in prostate cancer. Pathology International, 2020, 70, 441-451.	0.6	8

#	Article	IF	Citations
352	Surface-enhanced Raman spectroscopy of preoperative serum samples predicts Gleason grade group upgrade in biopsy Gleason grade group 1 prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 601.e1-601.e9.	0.8	5
353	The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. Archives of Pathology and Laboratory Medicine, 2021, 145, 461-493.	1.2	143
354	Urokinase-Type Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Noninvasive Evaluation of Aggressiveness: Comparison with Gleason Score in a Prospective Phase 2 Clinical Trial. Journal of Nuclear Medicine, 2021, 62, 354-359.	2.8	16
355	Cribriform architecture in radical prostatectomies predicts oncological outcome in Gleason score 8 prostate cancer patients. Modern Pathology, 2021, 34, 184-193.	2.9	32
356	Chromosome 5 harbors two independent deletion hotspots at 5q13 and 5q21 that characterize biologically different subsets of aggressive prostate cancer. International Journal of Cancer, 2021, 148, 748-758.	2.3	3
357	Prospect and adversity of artificial intelligence in urology. , 2021, , 309-337.		1
358	Current and emerging therapies for localized high-risk prostate cancer. Expert Review of Anticancer Therapy, 2021, 21, 267-282.	1.1	3
359	Comparison of TRUS and combined MRI–targeted plus systematic prostate biopsy for the concordance between biopsy and radical prostatectomy pathology. International Journal of Clinical Practice, 2021, 75, e13797.	0.8	7
360	How to Pick Out the â€œUnrealâ€•Gleason 3â€‰+â€‰3 Patients: A Nomogram for More Precise Active Surveillance Protocol in Low-Risk Prostate Cancer in a Chinese Population. Journal of Investigative Surgery, 2021, 34, 583-589.	0.6	9
361	The comparative effectiveness of mpMRI and MRI-guided biopsy vs regular biopsy in a population-based PSA testing: a modeling study. Scientific Reports, 2021, 11, 1801.	1.6	4
362	The predictive factor for pathological downgrading after prostatectomy in patients with biopsy Gleason score 4+3 or 4+4 prostate cancer. Molecular and Clinical Oncology, 2021, 14, 56.	0.4	4
363	Gleason grade 5 prostate cancer: sub-patterns and prognosis. Pathology, 2021, 53, 3-11.	0.3	6
364	Patient-level Prediction of Multi-classification Task at Prostate MRI based on End-to-End Framework learning from Diagnostic Logic of Radiologists. IEEE Transactions on Biomedical Engineering, 2021, 68, 1-1.	2.5	8
365	Old men with prostate cancer have higher risk of Gleason score upgrading and pathological upstaging after initial diagnosis: a systematic review and meta-analysis. World Journal of Surgical Oncology, 2021, 19, 18.	0.8	7
366	Precision diagnosis based on radiomics. , 2021, , 99-174.		0
367	The expression of YWHAZ and NDRG1 predicts aggressive outcome in human prostate cancer. Communications Biology, 2021, 4, 103.	2.0	13
368	Should Grade Group 1 (GG1) be called cancer?. World Journal of Urology, 2022, 40, 15-19.	1.2	11
369	Overexpression of the TRIM24 E3 Ubiquitin Ligase is Linked to Genetic Instability and Predicts Unfavorable Prognosis in Prostate Cancer. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, e29-e38.	0.6	6

#	Article	IF	Citations
370	Predicting Gleason sum upgrading from biopsy to radical prostatectomy pathology: a new nomogram and its internal validation. BMC Urology, 2021, 21, 3.	0.6	7
371	Opposing prognostic relevance of junction plakoglobin in distinct prostate cancer patient subsets. Molecular Oncology, 2021, 15, 1956-1969.	2.1	5
372	The prognostic value of high-grade prostate cancer pattern on MRI-targeted biopsies: predictors for downgrading and importance of concomitant systematic biopsies. World Journal of Urology, 2021, 39, 3315-3321.	1.2	6
373	Emerging role of multiparametric magnetic resonance imaging in identifying clinically relevant localized prostate cancer. Current Opinion in Oncology, 2021, 33, 244-251.	1.1	4
374	Gleason Grade Group Concordance between Preoperative Targeted Biopsy and Radical Prostatectomy Histopathologic Analysis: A Comparison Between In-Bore MRI-guided and MRIâ€"Transrectal US Fusion Prostate Biopsies. Radiology Imaging Cancer, 2021, 3, e200123.	0.7	12
375	Correlation of Likert scores IIIâ€"V with increasingly worse pathology in radical prostatectomy specimens significant only for men aged <60 or PSAD >0.15, with age <60 as good as PSAD <0.15 at discriminating lower risk in Likert III. Journal of Clinical Urology, 0, , 205141582199510.	0.1	0
376	Using Prostate Imaging-Reporting and Data System (PI-RADS) Scores to Select an Optimal Prostate Biopsy Method: A Secondary Analysis of the Trio Study. European Urology Oncology, 2022, 5, 176-186.	2.6	24
377	Age and gleason score upgrading between prostate biopsy and radical prostatectomy: Is this still true in the multiparametric resonance imaging era?. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 784.e1-784.e9.	0.8	7
378	The Primacy of High B-Value 3T-DWI Radiomics in the Prediction of Clinically Significant Prostate Cancer. Diagnostics, 2021, 11, 739.	1.3	14
379	Factors associated with higher prostate biopsy yield: when is software-assisted fusion MRI-targeting necessary?. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 234.e15-234.e19.	0.8	3
380	How Much Reliable Is the Current Belief on Grade Group 1 Prostate Cancer?. Pathology and Oncology Research, 2021, 27, 629489.	0.9	0
381	Negative Predictive Value of Biparametric Prostate Magnetic Resonance Imaging in Excluding Significant Prostate Cancer: A Pooled Data Analysis Based on Clinical Data from Four Prospective, Registered Studies. European Urology Focus, 2021, 7, 522-531.	1.6	10
382	Combined Systematic and MRI-US Fusion Prostate Biopsy Has the Highest Grading Accuracy When Compared to Final Pathology. Medicina (Lithuania), 2021, 57, 519.	0.8	5
383	Urine Biomarkers for Prostate Cancer Diagnosis and Progression. SociÃ©tÃ© Internationale D'urologie Journal, 2021, 2, 159-170.	0.2	0
384	Correlation of the Grade Group of Prostate Cancer according to the International Society of Urological Pathology (Isup) 2014 Classification between Prostate Biopsy and Radical Prostatectomy Specimens. Cancer Investigation, 2021, 39, 521-528.	0.6	1
385	Costâ€effectiveness of multiparametric magnetic resonance imaging and MRIâ€guided biopsy in a populationâ€based prostate cancer screening setting using a microâ€simulation model. Cancer Medicine, 2021, 10, 4046-4053.	1.3	4
386	Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naÃ¯ve men. Prostate Cancer and Prostatic Diseases, 2021, 24, 1110-1119.	2.0	40
387	Clinical significance and risk factors of International Society of Urological Pathology (ISUP) grade upgrading in prostate cancer patients undergoing robot-assisted radical prostatectomy. BMC Cancer, 2021, 21, 501.	1.1	6

#	Article	IF	Citations
388	Reply to: Axel Heidenreich. Still Unanswered: The Role of Extended Pelvic Lymphadenectomy in Improving Oncological Outcomes in Prostate Cancer. Eur Urol 2021;79:605â€"6. European Urology, 2021, 79, 607-608.	0.9	0
389	Prognostic value of FUS immunoexpression for Gleason patterns and prostatic adenocarcinoma progression. Annals of Diagnostic Pathology, 2021, 52, 151729.	0.6	2
390	New TRUS Techniques and Imaging Features of PI-RADS 4 or 5: Influence on Tumor Targeting. Frontiers in Oncology, 2021, 11, 608409.	1.3	4
391	Immunohistochemical investigation of cytokine expression levels as biomarkers in transrectal ultrasoundâ€'guided needle biopsy specimens of prostate adenocarcinoma. Molecular and Clinical Oncology, 2021, 15, 191.	0.4	3
392	In-bore MRI-guided prostate biopsy in a patient group with PI-RADS 4 and 5 targets: A single center experience. European Journal of Radiology, 2021, 141, 109785.	1.2	6
393	Role of prostate health index to predict Gleason score upgrading and high-risk prostate cancer in radical prostatectomy specimens. Scientific Reports, 2021, 11, 17447.	1.6	3
394	Proteomic discovery of non-invasive biomarkers of localized prostate cancer using mass spectrometry. Nature Reviews Urology, 2021, 18, 707-724.	1.9	25
395	Endogenous testosterone density predicts unfavorable disease at final pathology in intermediate risk prostate cancer. International Urology and Nephrology, 2021, 53, 2517-2526.	0.6	3
396	Correlation of prostate tumor eccentricity and Gleason scoring from prostatectomy and multi-parametric-magnetic resonance imaging. Quantitative Imaging in Medicine and Surgery, 2021, 11, 4235-4244.	1.1	8
397	Utility of T2-weighted MRI texture analysis in assessment of peripheral zone prostate cancer aggressiveness: a single-arm, multicenter study. Scientific Reports, 2021, 11, 2085.	1.6	11
398	Contemporary Gleason Grading System. , 2015, , 13-32.		3
399	Classifying Cancer Grades Using Temporal Ultrasound for Transrectal Prostate Biopsy. Lecture Notes in Computer Science, 2016, , 653-661.	1.0	7
400	Gleason 6 Tumors Should Still Be Labeled as Cancer. Current Clinical Urology, 2018, , 41-52.	0.0	1
401	Postoperative change in Gleason score of prostate cancer in fusion targeted biopsy: a matched pair analysis. Scandinavian Journal of Urology, 2021, 55, 27-32.	0.6	4
402	Clinical Validation of IsoPSAâ„¢, a Single Parameter, Structure Based Assay for Improved Detection of High Grade Prostate Cancer. Journal of Urology, 2019, 201, 1115-1120.	0.2	13
403	Ki67 in Gleason Pattern 3 as a Marker of the Presence of Higher-Grade Prostate Cancer. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 112-117.	0.6	11
404	Advantages of Evaluating Mean Nuclear Volume as an Adjunct Parameter in Prostate Cancer. PLoS ONE, 2014, 9, e102156.	1.1	4
405	Pathological Features of Localized Prostate Cancer in China: A Contemporary Analysis of Radical Prostatectomy Specimens. PLoS ONE, 2015, 10, e0121076.	1.1	18

#	Article	IF	Citations
406	Up regulation of Rho-associated coiled-coil containing kinase1 (ROCK1) is associated with genetic instability and poor prognosis in prostate cancer. Aging, 2019, 11, 7859-7879.	1.4	28
407	Deletion of 18q is a strong and independent prognostic feature in prostate cancer. Oncotarget, 2016, 7, 86339-86349.	0.8	24
408	A nuclear shift of GSK3Î² protein is an independent prognostic factor in prostate cancer. Oncotarget, 2019, 10, 1729-1744.	0.8	2
409	Assessing Expression of MUC1 and ZAG Protein Biomarkers in Prostate Biopsies Improves Prediction of Adverse Pathology Following Radical Prostatectomy. The Open Prostate Cancer Journal, 2015, 8, 1-9.	0.4	1
410	Multiparametric-Magnetic Resonance/Ultrasound Fusion Targeted Prostate Biopsy Improves Agreement Between Biopsy and Radical Prostatectomy Gleason Score. Anticancer Research, 2016, 36, 4833-4840.	0.5	42
411	Serum Testosterone Level Can Be Predictive Factor for Upstaging in Clinically Localized Prostate Cancer. The Korean Journal of Urological Oncology, 2020, 18, 116-123.	0.1	1
412	Risk of Gleason Score 3+4=7 prostate cancer upgrading at radical prostatectomy is significantly reduced by targeted versus standard biopsy. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 360-368.	3.9	17
413	The role of additional standard biopsy in the MRI-targeted biopsy era. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 637-639.	3.9	12
414	Upregulation of SPDEF is associated with poor prognosis in prostate cancer. Oncology Letters, 2019, 18, 5107-5118.	0.8	9
415	Health Economic Impact and Prospective Clinical Utility of Oncotype DXÂ® Genomic Prostate Score. Reviews in Urology, 2016, 18, 123-132.	0.9	28
416	The Use of Biomarkers in Prostate Cancer Screening and Treatment. Reviews in Urology, 2017, 19, 221-234.	0.9	51
417	Current clinical challenges in prostate cancer. Translational Andrology and Urology, 2013, 2, 122-36.	0.6	34
418	The current and future role of magnetic resonance imaging in prostate cancer detection and management. Translational Andrology and Urology, 2015, 4, 326-41.	0.6	29
419	The effect of metabolic syndrome on prostate cancer final pathology. Journal of Cancer Research and Therapeutics, 2019, 15, 47.	0.3	4
420	Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results. Asian Journal of Andrology, 2016, 18, 16.	0.8	64
421	Low serum testosterone predicts upgrading and upstaging of prostate cancer after radical prostatectomy. Asian Journal of Andrology, 2016, 18, 639.	0.8	18
422	MicroRNA expression and function in prostate cancer: a review of current knowledge and opportunities for discovery. Asian Journal of Andrology, 2016, 18, 559.	0.8	43
423	Prostate cancer upgrading or downgrading of biopsy Gleason scores at radical prostatectomy: prediction of â€œregression to the meanâ€•using routine clinical features with correlating biochemical relapse rates. Asian Journal of Andrology, 2019, 21, 598.	0.8	11

#	ARTICLE	IF	CITATIONS
424	Does extent of prostate-specific antigen fluctuation can predict Gleason score upgrading in low-risk prostate cancer patients?. Turkish Journal of Urology, 2019, 45, 42-48.	1.3	1
425	How Precisely Can Prostate Cancer Be Managed?. International Neurourology Journal, 2016, 20, S120-130.	0.5	10
426	Radiologist-like artificial intelligence for grade group prediction of radical prostatectomy for reducing upgrading and downgrading from biopsy. Theranostics, 2020, 10, 10200-10212.	4.6	22
427	Prostate tumor eccentricity predicts Gleason score better than prostate tumor volume. Quantitative Imaging in Medicine and Surgery, 2022, 12, 1096-1108.	1.1	6
428	Gleason grade accuracy of transperineal and transrectal prostate biopsies in MRI-naïve patients. International Urology and Nephrology, 2021, 53, 2445-2452.	0.6	5
429	Prostate zones and cancer: lost in transition?. Nature Reviews Urology, 2022, 19, 101-115.	1.9	25
430	Single Positive Core Prostate Cancer Has Less Aggressive Pathologic Features than Multiple Positive Core Prostate Cancer but Should It Still Be Considered an Indolent Tumor?. Open Journal of Urology, 2014, 04, 71-77.	0.0	0
432	Prostata und Samenblasen. , 2016, , 139-194.		2
433	Should Gleason Score 6 Still Be Called Cancer?. , 2016, , 41-47.		0
434	TRUS Biopsy: Is There Still a Role?. , 2016, , 53-67.		0
435	Focal Therapy and Active Surveillance in Europe. Current Clinical Urology, 2017, , 57-74.	0.0	0
437	Incidence of Pathological Downgrading and Treatment Outcome After Radical Prostatectomy in Patients With Biopsy Confirmed High Gleason Score Prostate Cancer. The Korean Journal of Urological Oncology, 2017, 15, 79-84.	0.1	0
438	Risk-Based Selection for Active Surveillance. Current Clinical Urology, 2018, , 53-64.	0.0	0
439	May Radiomic Data Predict Prostate Cancer Aggressiveness?. Communications in Computer and Information Science, 2019, , 65-75.	0.4	1
440	Comparison of prostate biopsy pathology and radical prostatectomy pathologies. Dicle Medical Journal, 0, , 133-139.	0.2	2
441	Radiomics for Identification and Prediction in Metastatic Prostate Cancer: A Review of Studies. Frontiers in Oncology, 2021, 11, 771787.	1.3	23
442	Multiparametric MRI in the management of prostate cancer: an update—a narrative review. Gland Surgery, 2020, 9, 2321-2330.	0.5	6
443	Histopathological Ratios to Predict Gleason Score Agreement between Biopsy and Radical Prostatectomy. Diagnostics, 2021, 11, 10.	1.3	13

#	ARTICLE	IF	CITATIONS
444	The Urine Biomarker PUR-4 Is Positively Associated with the Amount of Gleason 4 in Human Prostate Cancers. Life, 2021, 11, 1172.	1.1	1
445	Prostate Pathology. , 2021, , 133-186.		0
446	Bayesian information criterion approximations to Bayes factors for univariate and multivariate logistic regression models. International Journal of Biostatistics, 2021, 17, 241-266.	0.4	11
447	Extracellular MicroRNA in liquid biopsy: applicability in cancer diagnosis and prevention. American Journal of Cancer Research, 2016, 6, 1461-93.	1.4	40
448	Patients' experience with MRI-guided in-bore biopsy versus TRUS-guided biopsy in prostate cancer: a pilot study. Ecancermedicalscience, 2020, 14, 1127.	0.6	0
449	MRI-targeted prostate biopsy: the next step forward!. Medicine and Pharmacy Reports, 2021, 94, 145-157.	0.2	0
450	The impact of surgical downgrading on prostate cancer recurrence: systematic review and analysis of a multiethnic population. World Journal of Urology, 2022, 40, 709-718.	1.2	3
451	Is Grade Group 1 (Gleason score 3â€Š+â€Š3â€Š=â€Š6) adenocarcinoma of the prostate really cancer?. Current Opinion in Urology, 2022, 32, 91-95.	0.9	11
452	Prostate Cancer Gleason Score From Biopsy to Radical Surgery: Can Ultrasound Shear Wave Elastography and Multiparametric Magnetic Resonance Imaging Narrow the Gap?. Frontiers in Oncology, 2021, 11, 740724.	1.3	2
453	Dual-tracer PET/CT-targeted, mpMRI-targeted, systematic biopsy, and combined biopsy for the diagnosis of prostate cancer: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2821-2832.	3.3	15
454	Advanced glycation endâ€products (AGEs) are lower in prostate tumor tissue and inversely related to proportion of West African ancestry. Prostate, 2021, , .	1.2	1
455	Initial Prostate Biopsy of Grade Group One. Urological Science, 2020, 31, 170-176.	0.2	0
456	Evaluation of multiparametric prostate magnetic resonance imaging findings in patients with aÂGleason score of 6 in transrectal ultrasonography-guided biopsy. Polish Journal of Radiology, 2021, 86, 608-613.	0.5	1
457	Role of MRI in Prostate Cancer Assessment. , 2021, , 81-94.		0
458	Patientsâ€™ experience with MRI-guided in-bore biopsy versus TRUS-guided biopsy in prostate cancer: a pilot study. Ecancermedicalscience, 2020, 14, 1127.	0.6	0
459	MRI-targeted prostate biopsy: the next step forward!. Medicine and Pharmacy Reports, 2021, 94, 145-157.	0.2	1
460	TRUS-Guided Target Biopsy for a PI-RADS 3â€“5 Index Lesion to Reduce Gleason Score Underestimation: A Propensity Score Matching Analysis. Frontiers in Oncology, 2021, 11, 824204.	1.3	4
461	Diagnostic Accuracy of Contemporary Selection Criteria in Prostate Cancer Patients Eligible for Active Surveillance: A Bayesian Network Meta-Analysis. Frontiers in Oncology, 2021, 11, 810736.	1.3	1

#	Article	IF	Citations
462	A clinical available decision support scheme for optimizing prostate biopsy based on mpMRI. Prostate Cancer and Prostatic Diseases, 2022, 25, 727-734.	2.0	5
463	Limited Adenocarcinoma of the Prostate on Needle Core Biopsy. Archives of Pathology and Laboratory Medicine, 2022, 146, 469-477.	1.2	3
464	The Influence of Endogenous Testosterone Density on Unfavorable Disease and Tumor Load at Final Pathology in Intermediate-Risk Prostate Cancer: Results in 338 Patients Treated with Radical Prostatectomy and Extended Pelvic Lymph Node Dissection. Urologia Internationalis, 2022, 106, 928-939.	0.6	2
465	Risk Factors of Patients with Prostate Cancer Upgrading for International Society of Urological Pathology Grade Group I After Radical Prostatectomy. Ãœroonkoloji BÃ¼lteni, 2022, 21, 10-13.	0.1	0
466	ProstAttention-Net: A deep attention model for prostate cancer segmentation by aggressiveness in MRI scans. Medical Image Analysis, 2022, 77, 102347.	7.0	44
467	Concordancia del puntaje de Gleason en biopsia transrectal de prÃ³stata vs prostatectomÃa radical. Revista Mexicana De Urologia, 2021, 81, 1-10.	0.0	0
468	Independent validation of a pre-specified four-kallikrein marker model for prediction of adverse pathology and biochemical recurrence. British Journal of Cancer, 2022, 126, 1004-1009.	2.9	2
469	Prostate Cancer and Low Back Acheâ€"Evidenced Role of Physiotherapy. Case Reports in Clinical Medicine, 2022, 11, 94-100.	0.1	0
470	Nomogram Predicting Adverse Pathology Outcome on Radical Prostatectomy in Low-Risk Prostate Cancer Men. Urology, 2022, 166, 189-195.	0.5	6
471	Concordancia entre el Puntaje Gleason de la Biopsia de PrÃ³stata y el Resultado HistopatolÃ³gico Final de la ProstatectomÃa Radical. , 2021, 9, 6-9.		0
472	Decision-making based on International Society of Urological Pathology Gleason-scores obtained from transrectal needle biopsy of the Prostate: How Accurate Could We Be ?. Celal Bayar Ãœniversitesi SaÄŸlÄ±k Bilimleri EnstitÃ¼sÃ¼ Dergisi, 0, , .	0.1	0
473	PITX1 Is a Regulator of TERT Expression in Prostate Cancer with Prognostic Power. Cancers, 2022, 14, 1267.	1.7	7
474	Machine Learning-Based Prediction of Pathological Upgrade From Combined Transperineal Systematic and MRI-Targeted Prostate Biopsy to Final Pathology: A Multicenter Retrospective Study. Frontiers in Oncology, 2022, 12, 785684.	1.3	1
475	The best prostate biopsy sampling systemâ€"fusion and systematic biopsy: A single center experience. Urologia, 2021, , 039156032110371.	0.3	0
476	Predicting the Performance of Concurrent Systematic Random Biopsies during Image Fusion Targeted Sampling of Multi-Parametric MRI Detected Prostate Cancer. A Prospective Study (PRESET Study). Cancers, 2022, 14, 1.	1.7	26
477	miR-145-5p: A Potential Biomarker in Predicting Gleason Upgrading of Prostate Biopsy Samples Scored 3+3=6. Cancer Management and Research, 2021, Volume 13, 9095-9106.	0.9	5
478	The Discrepancy between Needle Biopsy and Radical Prostatectomy Gleason Score in Patients with Prostate Cancer. Urology Journal, 2020, 18, 395-399.	0.3	3
479	Tumour microenvironment and focal therapy for prostate cancer. Current Opinion in Urology, 2022, 32, 248-253.	0.9	1

#	ARTICLE	IF	CITATIONS
480	Concordance between biparametric MRI, transperineal targeted plus systematic MRI-ultrasound fusion prostate biopsy, and radical prostatectomy pathology. Scientific Reports, 2022, 12, 6964.	1.6	2
481	ProstatectomÃa radical asistida por robot en el Centro MÃ©dico Naval. Experiencia inicial. Revista Mexicana De Urologia, 2019, 79, 1-12.	0.0	0
482	Low serum total testosterone level as a predictor of upgrading in low-risk prostate cancer patients after radical prostatectomy: A systematic review and meta-analysis. Investigative and Clinical Urology, 0, 63, .	1.0	0
483	Optimizing active surveillance for prostate cancer using partially observable Markov decision processes. European Journal of Operational Research, 2023, 305, 386-399.	3.5	8
484	Clinical Factors Associated With Pathological Grade GroupÂ1 Patients in D'Amico Intermediate-Risk Group Following Robot-Assisted Radical Prostatectomy: A Retrospective Multicenter Cohort Study in Japan (The MSUG94 Group). Clinical Genitourinary Cancer, 2022, 20, 593-600.	0.9	0
485	Renaming Gleason Score 6 Prostate to Noncancer: A Flawed Idea Scientifically and for Patient Care. Journal of Clinical Oncology, 2022, 40, 3106-3109.	0.8	16
486	Concordance between Gleason score of prostate biopsies and radical prostatectomy specimens and its predictive factors. Urologia, 0, , 039156032211184.	0.3	0
487	Prostate cancer grade downgrading at time of prostatectomy provides riskâ€stratification insight into future tumor behavior after prostatectomy. Prostate, 2022, 82, 1520-1528.	1.2	4
488	New strategy for the identification of prostate cancer: The combination of Proclarix and the prostate health index. Prostate, 2022, 82, 1469-1476.	1.2	9
489	Grade group 1 prostate cancer on biopsy: are we still missing aggressive disease in the era of image-directed therapy?. World Journal of Urology, 2022, 40, 2423-2429.	1.2	5
490	From Cognitive MR-Targeted Fusion Prostate Biopsy to Radical Prostatectomy: Incidence and Predictors of Gleason Grade Group Upgrading in a Chinese Cohort. BioMed Research International, 2022, 2022, 1-5.	0.9	1
491	Grading of prostate cancer: Evolution and changing concepts. Indian Journal of Health Sciences and Biomedical Research KLEU, 2022, 15, 192.	0.1	0
492	FACTORS PREDICTING A POSSIBLE INCREASE OF GLEASON SCORE AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH WELL-DIFFERENTIATED PROSTATE CANCER. Trakia Journal of Sciences, 2022, 20, 146-151.	0.0	0
493	Quality checkpoints in the MRI-directed prostate cancer diagnostic pathway. Nature Reviews Urology, 2023, 20, 9-22.	1.9	17
494	Expanded Parameters in Active Surveillance for Low-risk Papillary Thyroid Carcinoma. JAMA Oncology, 2022, 8, 1588.	3.4	27
495	Diagnostic utility of three Tesla diffusion tensor imaging in prostate cancer: correlation with Gleason score values. Egyptian Journal of Radiology and Nuclear Medicine, 2022, 53, .	0.3	0
496	Pathological Accuracy in Prostate Cancer: Single-Center Outcomes of 3 Different Magnetic Resonance Imaging-Targeted Biopsy Techniques and Random Systematic Biopsy. , 2022, 48, 346-353.		0
497	Patient-level grading prediction of prostate cancer from mp-MRI via GMINet. Computers in Biology and Medicine, 2022, 150, 106168.	3.9	2

#	ARTICLE	IF	CITATIONS
498	Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification. European Urology, 2023, 83, 301-303.	0.9	7
499	Significance of non-standardized magnetic resonance imaging abnormalities and subsequent targeted prostate cancer biopsy for pathologists: A retrospective observational study. Pathology Research and Practice, 2022, 240, 154188.	1.0	3
500	Clinical Predictors of Grade Group Upgrading for Radical Prostatectomy Specimens Compared to Those of Preoperative Needle Biopsy Specimens. Diagnostics, 2022, 12, 2760.	1.3	0
501	Prostate volume is an independent predictive factor in selecting low-risk prostate patients for active surveillance. Frontiers in Urology, 0, 2, .	0.2	0
502	High-throughput precision MRI assessment with integrated stack-ensemble deep learning can enhance the preoperative prediction of prostate cancer Gleason grade. British Journal of Cancer, 2023, 128, 1267-1277.	2.9	4
503	The CAPRA&PDE4D5/7/9 Prognostic Model Is Significantly Associated with Adverse Post-Surgical Pathology Outcomes. Cancers, 2023, 15, 262.	1.7	1
504	SINGLE CENTRE RETROSPECTIVE STUDY COMPARING MAGNETIC RESONANCE-TRANSRECTAL ULTRASOUND (TRUS) FUSION TARGETED AND SYSTEMATIC BIOPSY VERSUS CONVENTIONAL TRUS SYSTEMATIC BIOPSY FOR DETECTING PROSTATE CANCER. , 2022, , 4-9.		0
505	Integrin Expression in Localized Prostate Cancer: A TCGA and MSKCC Cohort-based Exploratory *In Silico* Analysis. Anticancer Research, 2023, 43, 417-428.	0.5	1
506	Should Gleason score six (GS6) tumours be labelled as nonâ€cancer?. International Journal of Urological Nursing, 2023, 17, 139-140.	0.1	0
507	Cribriform pattern and intraductal carcinoma of the prostate can have a clinicopathological impact, regardless of their percentage and/or number of cores. Human Pathology, 2023, 135, 99-107.	1.1	6
508	The prognostic nomogram for PSA-incongruent low-risk prostate cancer treated by radical prostatectomy. International Urology and Nephrology, 0, , .	0.6	0
510	The effect of the Gleason score change on biochemical progression-free survival. Scripta Scientifica Medica, 2022, 54, 18.	0.1	0
511	Editorial: Combining multiple non-invasive images and/or biochemical tests to predict prostate cancer aggressiveness. Frontiers in Oncology, 0, 13, .	1.3	0
513	Determination of Whether Apex or Non-Apex Prostate Cancer Is the Best Candidate for the Use of Prostate-Specific Antigen Density to Predict Pathological Grade Group Upgrading and Upstaging after Radical Prostatectomy. Journal of Clinical Medicine, 2023, 12, 1659.	1.0	0
514	Gleason Grade Group Concordance between Systematic Template Combining Magnetic Resonance Imaging Fusion Targeted Biopsy and Radical Prostatectomy Specimens: A Comparison of Transperineal and Transrectal Approaches. Urology, 2023, 175, 151-156.	0.5	3
515	Diagnostic performance of transperineal prostate targeted biopsy alone according to the PI-RADS score based on bi-parametric magnetic resonance imaging. Frontiers in Oncology, 0, 13, .	1.3	0
516	Somatic and germline aberrations in homologous recombination repair genes in Chinese prostate cancer patients. Frontiers in Oncology, 0, 13, .	1.3	0
517	Predictive Factors for Gleason Score Upgrading in Patients with Prostate Cancer after Radical Prostatectomy: A Systematic Review and Meta-Analysis. Urologia Internationalis, 2023, 107, 460-479.	0.6	1

#	ARTICLE	IF	CITATIONS
546	PFCA-Net: a post-fusion based cross-attention model for predicting PCa Gleason Group using multiparametric MRI. , 2023, , .		0
549	Histopathological and Molecular Markers in the Assessment of Prostate Cancer Aggressivity. , 2024, , 179-206.		0